ImmunityBio

Historical price data

ImmunityBio, founded in 2014 by Dr. Patrick Soon-Shiong, is pioneering immunotherapy 2.0 with a 'triangle offense' approach that simultaneously activates NK cells, T cells, and other immune effectors. The company achieved a major milestone with FDA approval of ANKTIVA® for bladder cancer in April 2024, demonstrating 71% complete response rates and over 90% bladder preservation. With 18 trials in Phase 2 or 3 development and expanding global presence through recent approvals in Europe, Saudi Arabia, and Macau, ImmunityBio is positioned as a leader in the next generation of cancer immunotherapy. The company's platforms address multiple solid tumors and infectious diseases including HIV, representing significant market opportunities beyond their initial bladder cancer indication.

Multi-modal immunotherapy platform featuring ANKTIVA® (IL-15 superagonist), activated NK cell therapies, and adenoviral cancer vaccines designed to create a 'triangle offense' activating both innate and adaptive immune responses while preserving immune system integrity.

81 drugs in pipeline, 5 in Phase 3

ImmunityBio differentiates in the competitive immunotherapy space through its first-in-class IL-15 agonist platform, multi-modal triangle offense approach, and proven clinical efficacy with 71% complete response rates in bladder cancer. Main competitors include checkpoint inhibitor leaders like Bristol Myers Squibb and Merck, CAR-T companies like Gilead Sciences, and emerging immunotherapy platforms, though ImmunityBio's unique mechanism and clinical validation provide competitive advantages.